Role of cardiovascular intervention as a bridge to liver transplantation

Zankhana Raval1, Matthew E Harinstein1, James D Flaherty1

  • 1Zankhana Raval, James D Flaherty, Bluhm Cardiovascular Institute, Feinberg School of Medicine of Northwestern University, Chicago, IL 60611, United States.

Insights

Patients with end-stage liver disease (ESLD) have significant cardiovascular issues impacting transplant readiness. This review details diagnosing and managing heart and lung conditions to improve perioperative outcomes for liver transplant candidates.

Area of Science:

  • Cardiology
  • Hepatology
  • Transplantation Medicine

Background:

  • End-stage liver disease (ESLD) is linked to complex cardiovascular physiological changes.
  • These changes significantly affect perioperative outcomes and preoperative management strategies.
  • Cardiovascular disease is highly prevalent in patients with ESLD.

Purpose of the Study:

  • To review evidence-based diagnosis and management of cardiovascular disease in ESLD patients.
  • To focus on strategies bridging patients to liver transplantation.
  • To optimize perioperative cardiovascular health and outcomes.

Main Methods:

  • Review of existing literature on cardiovascular disease in ESLD.
  • Analysis of diagnostic criteria and predictors of outcomes post-liver transplant.
  • Evaluation of noninvasive and invasive testing modalities in ESLD.
  • Outline of evidence-based management approaches for ischemia, heart failure, and pulmonary vascular disease.

Main Results:

  • ESLD presents unique cardiovascular derangements affecting diagnostic test accuracy.
  • Traditional and non-traditional factors predict cardiovascular outcomes after liver transplantation.
  • Specific management strategies are crucial for bridging patients to transplant.

Conclusions:

  • An evidence-based approach to cardiovascular disease management is essential for ESLD patients.
  • Optimizing cardiovascular health improves the safety and success of liver transplantation.
  • Proactive management can enhance perioperative outcomes and long-term cardiovascular health.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
746
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
630
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
701
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
821
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
379